147 related articles for article (PubMed ID: 6214446)
41. [Repeated arterial infusion of zinostatin stimalamer using port for advanced hepatocellular carcinoma].
Yoshikawa M; Ebara M; Fukuda H; Sugiura N; Saisho H
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():30-3. PubMed ID: 9512684
[TBL] [Abstract][Full Text] [Related]
42. Stimulation of macrophage by polyanions and its conjugated proteins and effect on cell membrane.
Oda T; Morinaga T; Maeda H
Proc Soc Exp Biol Med; 1986 Jan; 181(1):9-17. PubMed ID: 2935880
[TBL] [Abstract][Full Text] [Related]
43. [Targeted chemotherapy of hepatocellular carcinoma with SMANCS/Lipiodol--how to use SMANCS/Lipiodol].
Konno T; Tabaru K; Isogai M; Nagamitsu A; Oda T
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():10-8. PubMed ID: 9512681
[TBL] [Abstract][Full Text] [Related]
44. Antitumor resistance induced by zinostatin stimalamer (ZSS), a polymer-conjugated neocarzinostatin (NCS) derivative. I. Meth A tumor eradication and tumor-neutralizing activity in mice pretreated with ZSS or NCS.
Masuda E; Maeda H
Cancer Immunol Immunother; 1995 May; 40(5):329-38. PubMed ID: 7600566
[TBL] [Abstract][Full Text] [Related]
45. [Combination of transcatheter arterial infusion of SMANCS and embolization (SMANCS-TAE) for hepatocellular carcinoma].
Hirashima N
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():125-32. PubMed ID: 9512700
[TBL] [Abstract][Full Text] [Related]
46. [Action mechanisms of zinostatin stimalamer (YM881)].
Tanaka S; Numasaki Y; Maeda H
Gan To Kagaku Ryoho; 1991 Oct; 18(13):2295-300. PubMed ID: 1834022
[TBL] [Abstract][Full Text] [Related]
47. SMANCS.
Duncan R
Jpn J Cancer Res; 1995 Jun; 86(6):inside front cover. PubMed ID: 7622412
[No Abstract] [Full Text] [Related]
48. [Effect of arterial administration of a high molecular weight anti-tumor agent styrene maleic acid neocarzinostatin for multiple small liver cancer].
Ikeda K; Saitoh S; Kumada H
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():19-23. PubMed ID: 9512682
[TBL] [Abstract][Full Text] [Related]
49. [Arterial infusion chemotherapy with SMANCS-Lipiodol for multiple hepatocellular carcinoma].
Takizawa K; Honda M; Obuchi M; Matsuoka S; Shima H; Uchiyama K; Hasebe S; Doai K; Satoh S; Kuniyasu Y
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():24-9. PubMed ID: 9512683
[TBL] [Abstract][Full Text] [Related]
50. [A preliminary report on the treatment of pleural carcinomatosis with SMANCS].
Kimura M; Kaneda H; Kume S; Matsushita H; Inoue M; Kai M; Takeuchi H; Uemura K
Gan To Kagaku Ryoho; 2001 Jul; 28(7):1023-5. PubMed ID: 11478133
[TBL] [Abstract][Full Text] [Related]
51. [Our initial experience with SMANCS in TAE for liver cancer].
Fujita M; Inoue E; Kuroda C; Kasugai H; Sasaki Y; Nakano H; Imaoka S
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():105-8. PubMed ID: 9512697
[TBL] [Abstract][Full Text] [Related]
52. [Arterial infusion of SMANCS-Lipiodol for advanced hepatocellular carcinoma].
Miura K; Nakao N; Yoshimoto A; Yamano T; Inoue J; Takayasu Y
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():51-5. PubMed ID: 9512688
[TBL] [Abstract][Full Text] [Related]
53. [Treatment of hepatocellular carcinoma by segmental SMANCS Lipiodol-TAE].
Hayashi T; Uchida H; Matsuo N; Sakaguchi H; Anai H; Tanaka T; Yamamoto T; Ooue S; Yoshioka T; Makutani S; Oishi H
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():116-24. PubMed ID: 9512699
[TBL] [Abstract][Full Text] [Related]
54. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS.
Maeda H; Sawa T; Konno T
J Control Release; 2001 Jul; 74(1-3):47-61. PubMed ID: 11489482
[TBL] [Abstract][Full Text] [Related]
55. Neocarzinostatin chromophore. Assignment of spectral properties and structural requirements for binding to DNA.
Napier MA; Goldberg IH
Mol Pharmacol; 1983 Mar; 23(2):500-10. PubMed ID: 6220205
[TBL] [Abstract][Full Text] [Related]
56. [Efficiency of segmental SMANCS/Lip-TAE for hepatocellular carcinoma--comparative studies in the efficacy of segmental SMANCS/Lip-TAI].
Matoba M; Mitsuya T; Ichiyanagi K; Morita M; Kidani E; Ibe N; Tatsumi Y; Tamamura H; Nakagawa T; Okimura T; Yamamoto I
Gan To Kagaku Ryoho; 1997 Jan; 24(1):37-42. PubMed ID: 9020943
[TBL] [Abstract][Full Text] [Related]
57. [Comparison of therapeutic effects of SMANCS (+TAE) and Non-SMANCS/LpTAE].
Nabeshima M; Ochi J; Hikita H; Nishikawa H; Ohara T; Torii A; Fujita S; Takeda J; Miura K
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():99-104. PubMed ID: 9512696
[TBL] [Abstract][Full Text] [Related]
58. [Intra-arterial infusion of SMANCS for treatment of patients with hepatocellular carcinoma--adverse reactions and complications].
Sakaguchi T; Yoshimatsu S; Sagara K; Yamashita Y; Takahashi M
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():64-9. PubMed ID: 9512690
[TBL] [Abstract][Full Text] [Related]
59. [Significance of arterial infusion of SMANCS-dissolved Lipiodol in therapeutic strategies for hepatocellular carcinoma].
Jin-no K
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():90-8. PubMed ID: 9512695
[TBL] [Abstract][Full Text] [Related]
60. [Histological effect of SMANCS/LPD therapy in renal cell carcinoma].
Suzuki T; Kobayashi M; Nakamura T; Takahashi O; Imai K; Yamanaka H; Suzuki K; Konno T; Maeda H
Nihon Gan Chiryo Gakkai Shi; 1987 Oct; 22(9):2210-7. PubMed ID: 2833546
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
